Literature DB >> 7123491

Totally implanted venous and arterial access system to replace external catheters in cancer treatment.

J E Niederhuber, W Ensminger, J W Gyves, M Liepman, K Doan, E Cozzi.   

Abstract

A totally implanted venous and arterial access system was tested in 30 cancer patients. The device, an injection port (Infuse-A-Port, Infusaid Corp., Sharon, Mass.), consisted of a 3.5 by 1.5 cm conical chamber with a self-sealing silicone rubber septum connected to a Silastic catheter. Ten patents had the injection port operatively placed for arterial access. A total of 39 bolus injections and 18 continuous infusions lasting an average 5.4 +/- 3.4 days were administered through the port. The total time of arterial access ranged from 70 to 370 days. No special program of heparinization was required to maintain patency. The injection port was used for central venous access in 20 patients. The first six patients had a small lumen catheter of 0.38 mm internal diameter, and five had occlusion between 142 and 447 days. Subsequently, 19 ports with a larger catheter lumen of 0.63 mm were used. These ports functioned for an average of 274 +/- 110 days (23 to 382 days). There were 380 single bolus injections and 64 continuous infusions. A variety of anticancer agents as well as whole blood, blood products, and antibiotics were administered with the device without difficulty. Patient acceptance was excellent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7123491

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  99 in total

1.  Outcome analysis in 3,160 implantations of radiologically guided placements of totally implantable central venous port systems.

Authors:  Ulf K M Teichgräber; Stephan Kausche; Sebastian N Nagel; Bernhard Gebauer
Journal:  Eur Radiol       Date:  2011-01-05       Impact factor: 5.315

2.  Femoral placement of totally implantable venous power ports as an alternative implantation site for patients with central vein occlusions.

Authors:  Jan P Goltz; Hendrik Janssen; Bernhard Petritsch; Ralph Kickuth
Journal:  Support Care Cancer       Date:  2013-09-24       Impact factor: 3.603

3.  Catheter Fracture of Subclavian Venous Chemoport Device at Costoclavicular Junction: Pinch-off Syndrome.

Authors:  Vineet Goel; Naveen Kumar; Vivek Saxena; Harit Chaturvedi
Journal:  Indian J Surg Oncol       Date:  2018-07-30

4.  Catheter fracture of intravenous ports and its management.

Authors:  Ching-Yang Wu; Jui-Ying Fu; Po-Hao Feng; Tsung-Chi Kao; Sheng-Yueh Yu; Hao-Jui Li; Po-Jen Ko; Hung-Chang Hsieh
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

5.  Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis.

Authors:  B Yung; J S Elborn; I A Campbell; Y Summers; M Beckles; A A Woodcock
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

6.  Arm port implantation in cancer patients.

Authors:  Pierre-Yves Marcy; Andrea Figl; Nicolas Amoretti; Antoine Ianessi
Journal:  Int J Clin Oncol       Date:  2010-03-02       Impact factor: 3.402

7.  Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients.

Authors:  M A de Gregorio; J M Miguelena; J A Fernández; C de Gregorio; A Tres; E R Alfonso
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

8.  Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis.

Authors:  K L Fraser; H Grosman; R H Hyland; D E Tullis
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

9.  Intrahepatic distant metastasis and metachronous multicentric occurrence in solitary hepatocellular carcinoma of less than five centimeters in diameter.

Authors:  M Yamamoto; M Matsuda; Y Iimuro; H Fujii; K Nagahori; T Ainota
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

10.  Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.

Authors:  Yoichiro Yoshida; Seiichiro Hoshino; Naoya Aisu; Masayasu Naito; Syu Tanimura; Ai Mogi; Toshihiro Tanaka; Keiji Hirata; Kazuo Tamura; Yuichi Yamashita
Journal:  Int J Clin Oncol       Date:  2014-05-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.